Bioingenium
Bioingenium is a Contract Development and Manufacturing Organisation (CDMO) specializing in bioprocess development and recombinant therapeutic proteins production using bacterial, mammalian, and yeast expression systems. Founded in 2008 in Barcelona, the company has extensive experience in decoding DNA to proteins, scaling up production, and meeting drug and vaccine manufacturing needs. With a focus on quality, flexibility, and customer satisfaction, Bioingenium serves the biopharmaceutical, cosmetics, and food industries worldwide, with presence in over 20 countries. The company invests in state-of-the-art facilities and collaborates with leading partners to develop innovative bioprocesses and active ingredients.
Industries
Nr. of Employees
small (1-50)
Bioingenium
Passeig dels Ferrocarrils Catalans, 141 Cornellà de Llobregat (08940) Barcelona, Spain
Products
Streptolysin O (SLO)
Listed product in company's product portfolio (product page available); specific technical or formulation details are provided on the product page.
Streptolysin O (SLO)
Listed product in company's product portfolio (product page available); specific technical or formulation details are provided on the product page.
Services
Design and generation of expression constructs, molecular cloning, and production and characterization of cell banks for bacterial, mammalian and yeast expression systems.
End-to-end development of upstream fermentation and downstream purification workflows including bioreactor cultivations, filtration, and multi-mode chromatographic separations to produce drug substance and drug product.
Scale-up services from laboratory to pilot production, preparation of preclinical batches and support for transfer to GMP manufacturing facilities.
Analytical packages for biologics including identity, purity and potency assessment, forced-degradation studies, and accelerated and long-term stability testing; formulation development for liquid and lyophilised formats.
End-to-end contract development and manufacturing services for biologics covering cell line development, process development, analysis, scale-up and transfer to GMP.
Development and manufacturing of biotechnology-derived active ingredients for cosmetics using fermentation, purification and molecular characterization to ensure reproducibility and quality.
Design and generation of expression constructs, molecular cloning, and production and characterization of cell banks for bacterial, mammalian and yeast expression systems.
End-to-end development of upstream fermentation and downstream purification workflows including bioreactor cultivations, filtration, and multi-mode chromatographic separations to produce drug substance and drug product.
Scale-up services from laboratory to pilot production, preparation of preclinical batches and support for transfer to GMP manufacturing facilities.
Analytical packages for biologics including identity, purity and potency assessment, forced-degradation studies, and accelerated and long-term stability testing; formulation development for liquid and lyophilised formats.
End-to-end contract development and manufacturing services for biologics covering cell line development, process development, analysis, scale-up and transfer to GMP.
Development and manufacturing of biotechnology-derived active ingredients for cosmetics using fermentation, purification and molecular characterization to ensure reproducibility and quality.
Expertise Areas
- Recombinant protein expression
- Bioprocess development (upstream and downstream)
- Cell line and strain engineering
- Upstream fermentation and bioreactor process control
Key Technologies
- Escherichia coli expression
- CHO and HEK mammalian expression
- Pichia pastoris yeast expression
- Batch and fed-batch fermentation
News & Updates
Bioingenium's Business Development team attended BIO Europe in Leipzig, Germany, engaging in partnering meetings and networking with industry professionals.
Bioingenium participated in Bio Japan 2022 expo, showcasing their bioprocessing solutions and networking with biotech companies in Tokyo.
Bioingenium announced their participation with their own booth at Bio Spain 2023 in Barcelona, scheduled for September 26-28, 2023.
Bioingenium invests €1.5 million in a new 1200 m2 bioprocess plant in Cornellà, Barcelona, to expand production capacity for biopharmaceutical and cosmetic active ingredients.
Bioingenium is part of the PANACEA program of CDTI for R&D of new natural active ingredients, with plans to expand their active ingredient platform.
Bioingenium receives financial support from ACCIÓ and the Department of Business and Work for their new bioprocess plant in Cornellà, Barcelona.
Bioingenium's Business Development team attended BIO Europe in Leipzig, Germany, engaging in partnering meetings and networking with industry professionals.
Bioingenium participated in Bio Japan 2022 expo, showcasing their bioprocessing solutions and networking with biotech companies in Tokyo.
Bioingenium announced their participation with their own booth at Bio Spain 2023 in Barcelona, scheduled for September 26-28, 2023.
Bioingenium invests €1.5 million in a new 1200 m2 bioprocess plant in Cornellà, Barcelona, to expand production capacity for biopharmaceutical and cosmetic active ingredients.
Bioingenium is part of the PANACEA program of CDTI for R&D of new natural active ingredients, with plans to expand their active ingredient platform.
Bioingenium receives financial support from ACCIÓ and the Department of Business and Work for their new bioprocess plant in Cornellà, Barcelona.